Aclaris Therapeutics Inc. (ACRS) is priced at $18.54 after the most recent trading session. At the very opening of the session, the stock price was $18.11 and reached a high price of $18.63, prior to closing the session it reached the value of $17.76. The stock touched a low price of $16.82.
Recently in News on June 10, 2021, Aclaris Announces Pricing of Public Offering of Common Stock. Aclaris Therapeutics, Inc. (Nasdaq:ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory diseases, today announced the pricing of its underwritten public offering of 7,042,254 shares of its common stock at a price to the public of $17.75 per share. In addition, Aclaris has granted to the underwriters a 30-day option to purchase up to 1,056,338 additional shares of common stock at the public offering price, less the underwriting discount. The gross proceeds from the offering to Aclaris are expected to be approximately $125.0 million, before deducting underwriting discounts and commissions and offering expenses, but excluding any exercise of the underwriters’ option. The offering is expected to close on or about June 14, 2021, subject to customary closing conditions. You can read further details here
Aclaris Therapeutics Inc. had a pretty favorable run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $30.38 on 04/08/21, with the lowest value was $5.65 for the same time period, recorded on 01/13/21.
Aclaris Therapeutics Inc. (ACRS) full year performance was 1020.82%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Aclaris Therapeutics Inc. shares are logging -38.96% during the 52-week period from high price, and 1371.43% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $1.26 and $30.38.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 1151075 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Aclaris Therapeutics Inc. (ACRS) recorded performance in the market was 174.57%, having the revenues showcasing -22.15% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 933.02M, as it employees total of 60 workers.
Specialists analysis on Aclaris Therapeutics Inc. (ACRS)
During the last month, 0 analysts gave the Aclaris Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 23.11, with a change in the price was noted +12.65. In a similar fashion, Aclaris Therapeutics Inc. posted a movement of +215.22% for the period of last 100 days, recording 2,104,525 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for ACRS is recording 0.00 at the time of this writing. In addition, long term Debt to Equity ratio is set at 0.10.
Trends and Technical analysis: Aclaris Therapeutics Inc. (ACRS)
Raw Stochastic average of Aclaris Therapeutics Inc. in the period of last 50 days is set at 12.65%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 23.89%. In the last 20 days, the company’s Stochastic %K was 14.38% and its Stochastic %D was recorded 22.04%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be pessimistic, given the fact the metric is recording 174.57%. Additionally, trading for the stock in the period of the last six months notably improved by 333.29%, alongside a boost of 1020.82% for the period of the last 12 months. The shares increased approximately by -18.28% in the 7-day charts and went up by -23.79% in the period of the last 30 days. Common stock shares were lifted by -22.15% during last recorded quarter.